In the past six months evidence has accumulated identifying the Australia antigen with viral hepatitis.' Now scientific communications are appearing at such a rate that it may be helpful to the practising doctor to go back to the beginning of the story.
In 1961 B. S. Blumberg and his colleagues2 reported that patients who had received blood transfusions developed precipitating antibodies against serum beta-lipoproteins. These antibodies were found commonly in patients who had received large numbers of transfusions-for example, patients with thalassaemia. During a search for additional precipitating antibodies an antibody was detected in the serum of a transfused haemophiliac patient which was different from the lipoproteins previously discovered.5 This serum came from an Australian aborigine, and so the name "Australia antigen" was given to it. 6 Subsequent studies by B. S. Blumberg and his colleagues7 ' showed that the antigen was relatively rare in the blood of healthy people in North America and Europe (0 1 %) but was found with much higher frequency in apparently healthy people living in the tropics and southeast Asia. It was often found in patients with acute forms of lymphocytic and myelogenous leukaemia (13-18%), but not with chronic myeloid leukaemia. It was also detected in patients with lepromatous leprosy (9 %), in patients with thalassaemia and others who had received numerous transfusions, and in patients with Down's syndrome (mongolism), especially those living in institutions.78 In 1967 Blumberg and colleagues7 8 reported that the Australia (Au) antigen appeared to be associated with cases of acute viral hepatitis. The antigen was detected in about 20 % of cases of acute viral hepatitis, and, moreover, the antigen was detected in an individual after a blood transfusion. Recent studies indicated that the net was closing in on the association between the Au antigen and viral hepatitis,9 but this is not the complete story.
At first it appeared that Au antigen was present in the blood of patients suffering from both forms of viral hepatitis, serum and infectious. ' Almeida, who have contributed much to our knowledge of the subject in this country.2' 22 On electron-microscopy these workers found virus-like structures displaying the characteristics of the coronavirus group. Furthermore, all the particles appeared to consist of antigen-antibody complexes. It must be stressed that this is a single observation and will have to be confirmed, but if confirmation is forthcoming this could be a discovery of the greatest significance. Mouse hepatitis virus belongs to the coronavirus group, and the finding of similar morphological structures in a human serum clearly calls for further study.
Antibodies to mouse hepatitis can be found in human sera," but it is not clear whether these result from infection with rodent excreta, as for example occurs with lymphocytic choriomeningitis virus, or by infection with a human serotype of the mouse hepatitis virus. The latter is a possibility that has to be considered in relation to the aetiology of acute infectious (IH) hepatitis. So far all attempts to isolate the viruses of hepatitis, both IH and SH, have failed except in man but, as Zuckerman and his colleagues have shown by electron-microscopy studies, antigen-antibody complexes are often present. These may be responsible in part for the disease process; the antibody present may also inhibit virus growth in susceptible cells. This is exciting news and it is to be hoped that with the many new and specific techniques that have been developed we shall be hearing more of hepatitis antigens and the viruses responsible for hepatitis. If it can be proved that a corona-type virus is aetiologically related to infectious hepatitis, the next important step will be to isolate it by cultural methods. As well as being a step towards proving its identity this will be essential for developing measures of active immunization. Many 
